View source for Sandbox GGC11

==5CEQ DLK in complex with inhibitor 50F (2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile)==
<StructureSection load='5ceq' size='340' side='right'caption='[[5ceq]], [[Resolution|resolution]] 1.91&Aring;' scene=''>
5CEQ is a MAP3K12 protein from homo sapiens. It plays a role in the MAPK Cascade pathway mostly by interacting with the JNKs, SAPKs, and ERKs which are part of part of the MAP kinases. Since some of the MAP kinases are involved with the central nervous system signaling, it has been shown that DLK also plays a role in protection of neurons when inhibited by 50F.   

== Function ==
Regulates JNK/SAPK cascade, transferase phosphorylation 
== Disease ==
Neuron degenerative diseases such as Parkinson’s, and Alzheimer. 
== Relevance ==
This protein will help us understand more about the physiology of degenerative diseases, which will lead to making more medicine that could possibly slow the deterioration process, or even cure the diseases.
== Structural highlights ==
<scene name='78/781195/00ligand/1'>50F</scene>

<scene name='78/781195/01dfg_active_site/1'>active site</scene>

<scene name='78/781195/03asp161/1'>ASP161</scene>

</StructureSection>
Gene: MAP3K12 

Related proteins: 5CEO, 5CEN, Q12852

Ligand: 50F

== References ==
1. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y, Ma C, Scearce-Levie K, Ghosh AS, Shin YG, Solanoy H, Wang J, Wang B, Yin J, Siu M, Lewcock JW. Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). J Med Chem. 2015 Oct 2. PMID:26431428 doi:http://dx.doi.org/10.1021/acs.jmedchem.5b01072

2.  Cargnello, M., & Roux, P. P. (2011). Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and molecular biology reviews : MMBR, 75(1), 50–83. https://doi.org/10.1128/MMBR.00031-10

3. Siu M, Sengupta Ghosh A, Lewcock JW. Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration. J Med Chem. 2018 Sep 27;61(18):8078-8087. doi: 10.1021/acs.jmedchem.8b00370. Epub 2018 Jun 4. PMID: 29863360.

4. Patel S, Cohen F, Dean BJ, De La Torre K, Deshmukh G, Estrada AA, Ghosh AS, Gibbons P, Gustafson A, Huestis MP, Le Pichon CE, Lin H, Liu W, Liu X, Liu Y, Ly CQ, Lyssikatos JP, Ma C, Scearce-Levie K, Shin YG, Solanoy H, Stark KL, Wang J, Wang B, Zhao X, Lewcock JW, Siu M. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem. 2015 Jan 8;58(1):401-18. doi: 10.1021/jm5013984. Epub 2014 Oct 23. PMID: 25341110./>